David Katz, CIO at Matrix Asset Advisors, tells 'Worldwide Exchange' the market is jittery, tech looks overbought, and Pfizer ...

Pfizer acquired Seagen in 2023 for $43 billion, and shut down construction on a $350 million manufacturing facility the ...

Ahead of the threatened tariffs, front-running of orders looks to have been particularly steep in the pharmaceutical sector. Factory output recorded a strong rebound in May in Ireland, where pharma ...

The mRNA technology behind the Pfizer and Moderna vaccines are groundbreaking, but their potential goes way beyond COVID-19.

Hiding the Truth, from Farm to Fable,” reveals how the animal agriculture industry shielded itself from scrutiny.

US President Donald Trump has threatened to impose tariffs at a rate as high as 200pc on imported drugs on Tuesday night in ...

Australia’s Snowy 2.0 project’s newest Herrenknecht TBM – measuring 178m long, with eight trailing gantries, and a cutterhead ...

Global manufacturers are constantly revamping their network of plants. Surviving over the long term for a factory—especially ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing that his team went through individual scans and interviewed investigators ...

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and why it is a Buy.

Pfizer is in-licensing a bispecific antibody drug for cancer that China-based 3SBio designed to block the proteins PD-1 and VEGF. The deal puts the pharmaceutical giant in a growing group of ...